The latest price target for MoonLake (NASDAQ:MLTX) was reported by Leerink Partners on July 1, 2026. The analyst firm set a price target for $29.00 expecting MLTX to rise to within 12 months (a possible 47.36% upside). 32 analyst firms have reported ratings in the last year.

The latest analyst rating for MoonLake (NASDAQ:MLTX) was provided by Leerink Partners, and MoonLake maintained their outperform rating.

The last upgrade for MoonLake Immunotherapeutics happened on March 23, 2026 when Wolfe Research raised their price target to $24. Wolfe Research previously had an underperform for MoonLake Immunotherapeutics.

The last downgrade for MoonLake Immunotherapeutics happened on January 15, 2026 when Goldman Sachs changed their price target from $8 to $10 for MoonLake Immunotherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MoonLake, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MoonLake was filed on July 1, 2026 so you should expect the next rating to be made available sometime around July 1, 2027.

While ratings are subjective and will change, the latest MoonLake (MLTX) rating was a maintained with a price target of $24.00 to $29.00. The current price MoonLake (MLTX) is trading at is $19.68, which is out of the analyst’s predicted range.